PURPOSE:
To determine whether thalidomide therapy can prevent a recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy. METHODS: Case report. In a 38-year-old woman with bilateral punctate inner choroidopathy, tha lidomide therapy was initiated three days after laser photocoagulation of a choroidal neovascular membrane. RESULTS: The patient had a recurrence of the choroidal neovascular membrane eight months after the start of thalidomide therapy. CONCLUSIONS: The failure of thalidomide to prevent a recurrence of a choroidal neovascular membrane in this patient suggests that this medi cation may have only a limited benefit in prevent ing recurrences of choroidal neovascular mem branes. been an option in the past; however, the current Age-Related Macular Degeneration and Thalidomide Study is evaluating the potential of thalidomide as an adjuvant treatment of choroidal neovascular mem branes associated with age-related macular degenera tion.
P UNCTATE INNER CHOROIDOPATHY
A 38-year-old woman with bilateral punctate inner choroidopathy had multiple parafoveal and subfoveal choroidal neovascular membranes despite repeated sessions of laser photocoagulation. In an effort to preserve foveal vision in the patient's less severely affected right eye, a compassionate plea protocol was established to initiate thalidomide therapy after laser photocoagulation of a parafoveal choroidal neovascu lar membrane. At the start of therapy, the patient's best-corrected visual acuity was reduced to L.E.: 20/80 secondary to a recurrent subfoveal choroidal neovas cular membrane that had previously been treated with laser photocoagulation. Best-corrected visual acuity was R.E.: 20/20 but was threatened by a recurrent extrafoveal choroidal neovascular membrane.
The patient, who had had a hysterectomy, received 100 mg of thalidomide on a daily basis for eight months. Therapy was begun within three days of laser photocoagulation to her right eye (Fig. 1) . After eight months of therapy, metamorphopsia developed in the patient's right eye. Despite the absence of subretinal hemorrhage or fluid, a fluorescein angiogram con firmed the presence of a recurrent choroidal neovas cular membrane along the foveal edge of the previous laser scar (Fig. 2) . The time interval between laser therapy and this recurrence was not markedly differ ent from the intervals between previous recurrences in either eye. Thalidomide therapy was terminated and the recurrent lesion was successfully treated with laser photocoagulation. Best-corrected visual acuity after treatment was R.E.: 20/25 and was stable for six months. No further recurrences have thus far been detected.
Punctate inner choroidopathy is similar to the presumed ocular histoplasmosis syndrome, which tra ditionally has a better response to photocoagulation than age-related macular degeneration. In our pa tient, whose retinal pigment epithelium was not undergoing the progressive degenerative changes seen in advanced age-related macular degeneration, cho roidal neovascular membrane developed despite treat ment with daily doses of 100 mg of thalidomide. Optimal dosing for thalidomide has not been estab lished, and therapeutic levels of thalidomide may be greater than that used in our patient. 3, 4 The dosing regimen in the current Age-Related Macular Degen eration and Thalidomide Study is 100 mg per day for the first two weeks, followed by 200 mg per day thereafter (Ho AC, unpublished data, 1995). The Age-Related Macular Degeneration and Thalidomide Study is a prospective, placebo-controlled, random ized, double-blind, single-center study that will give further insight into the efficacy of thalidomide in the treatment of choroidal neovascularization for agerelated macular degeneration. However, the failure of thalidomide to prevent a recurrence of a choroidal neovascular membrane in our patient suggests that this medication may have only a limited benefit in preventing recurrences of choroidal neovascular membranes.
